Coherus Oncology (CHRS) Assets (2013 - 2026)

Coherus Oncology has disclosed Assets across 14 years of filings, most recently posting $191.2 million for Q2 2026.

• In Q2 2026, Assets fell 56.5% year-over-year to $191.2 million; the TTM figure through Jun 2026 stood at $191.2 million (down 56.5% YoY), while the FY2025 annual figure was $258.3 million, down 42.4% from the prior year.
• Assets came in at $191.2 million for Q2 2026 at Coherus Oncology, down from $266.0 million in the prior quarter.
• In the past five years, Assets ranged from a high of $763.5 million in Q1 2024 to a low of $191.2 million in Q2 2026.
• Average Assets over 5 years is $482.8 million, with a median of $492.9 million recorded in 2022.
• Year-over-year, Assets soared 89.74% in 2024 and slumped 56.5% in 2026.
• Over 5 years, Assets stood at $480.8 million in 2022, then jumped by 30.94% to $629.6 million in 2023, then retreated by 28.76% to $448.5 million in 2024, then sank by 42.4% to $258.3 million in 2025, then decreased by 26.0% to $191.2 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $191.2 million in Q2 2026, $266.0 million in Q1 2026, and $258.3 million in Q4 2025.